As of March 31, 2026, cash and cash equivalents and short-term investments were $90.4M, vs. $60.9M as of March 31, 2025. “We are pleased to have completed enrollment in our Phase 1 clinical trial of SL-325, and are looking forward to sharing a comprehensive data set on all single ascending dose and multiple ascending dose cohorts from this study in the second quarter of 2026, including safety and tolerability, pharmacokinetics, receptor occupancy, duration of receptor occupancy, pharmacodynamics, and immunogenicity data,” said CEO Taylor Schreiber.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Shattuck Labs initiated with an Overweight at Cantor Fitzgerald
- Shattuck Labs price target raised to $18 from $6 at H.C. Wainwright
- Shattuck Labs: Differentiated DR3 Antagonist SL-325 Positions Company for Upside in Emerging TL1A Immunology
- Shattuck Labs management to meet with Piper Sandler
- Citi ups Shattuck Labs target, opens ‘upside 90-day catalyst watch’